No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Communication Equipment
Ascom Holding AG, operating globally through its subsidiaries, specializes in providing information and communication technology (ICT) and mobile workflow solutions, primarily for the healthcare industry. Their comprehensive product portfolio features advanced nurse call and patient monitoring systems. This includes teleCARE IP, a multifaceted solution for nurse calls, alerts, messaging, patient tracking, and wander management, alongside Telligence, a dedicated patient response system. Ascom also develops Digistat software to streamline clinical workflows and Unite software, a powerful orchestration platform that seamlessly integrates data and events from diverse source systems, delivering alerts, chats, and tasks to users across various endpoint devices. Furthermore, the company supplies a range of mobile communication tools, such as DECT and VoWiFi handsets, pagers, and IP-DECT solutions. Complementing their technology, Ascom offers extensive services encompassing consulting, implementation, training, support, and maintenance. These solutions cater to a broad spectrum of clients, from acute care hospitals and long-term care facilities to enterprises in sectors like retail, security, and hospitality. The company's headquarters are situated in Baar, Switzerland.
www.ascom.comNo one on the platform currently holds ASCN.SW.
No tracked institution reports a position in ASCN.SW as of their last filing.
No one on the platform has traded ASCN.SW yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 34.1% | 23.4% | — | — | — | |
| Rev. Growth % | 1.9% | 0.8% | ||||
| Profit Margin % | 5.2% | 4.1% | -0.3% | |||
| Free Cash Flow Margin % | 10.8% | 4.1% | 4.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $299M | +2.4% | $0.42 | $0.37–$0.45 | — | 3 |
| 2027 | $306M | +2.3% | $0.47 | $0.42–$0.51 | — | 3 |
| 2028 | $316M | +3.2% | $0.48 | $0.46–$0.51 | — | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| $15M |
| — |
| MOLN.SWMolecular Partners AG | $3.21 | -1.83% | $120M | — |
| NWRN.SWNewron Pharmaceuticals S.p.A. | $10.86 | -1.81% | $226M | — |
Source: Financial Modeling Prep · peers by sector/industry